Triglycerides and Cardiovascular Risk
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
In 1996 a meta-analysis was published showing that an increase in plasma triglyceride (TG) levels was associated with an increase in CHD risk, even after adjustment for high density lipoprotein cholesterol (HDL-C) levels. Very recently, two studies were published that further extent the early observation and showed the importance of nonfasting plasma triglyceride (TG) levels in the prediction of risk on coronary heart disease (CHD). In the current review we have summarized all available evidence obtained in clinical studies showing that treatment guidelines should reconsider to include nonfasting TG in their risk assessments as nonfasting TG levels may better predict CVD risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.
Guilherme, A., Virbasius, J. V., Puri, V., & Czech, M. P. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2391 · Cited by 2,292 · cited 3×
“[20] Guilherme A, Virbasius JV, Puri V, et al.”
BackgroundInfluentialNordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408 · cited 3×
“A number of meta-analyses have been published showing independent associations between TG levels and CHD risk, independent of HDL-C levels [22, 29, 30].”
BackgroundResultHu, G. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.10.1066 · Cited by 1,135
Thematic review series: Glycerolipids. DGAT enzymes and triacylglycerol biosynthesis
Yen, C.-L. E., Stone, S. J., Koliwad, S., Harris, C., & Farese, R. V. (2008) · Journal of Lipid Research · doi:10.1194/jlr.r800018-jlr200 · Cited by 1,105
Diabetic dyslipidaemia: from basic research to clinical practice*
Taskinen, M.-R. (2003) · Diabetologia · doi:10.1007/s00125-003-1111-y · Cited by 888
Adiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160192 · Cited by 820 · cited 5×
“The hallmark of these clinical phenotypes is the presence of insulin resistance [10].”
BackgroundInfluentialLangsted, A., Freiberg, J. J., & Nordestgaard, B. G. (2008) · Circulation · doi:10.1161/circulationaha.108.804146 · Cited by 588
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
Kastelein, J. J. P., van der Steeg, W. A., Holme, I., Gaffney, M., Cater, N. B., Barter, P., Deedwania, P., Olsson, A. G., Boekholdt, S. M., Demicco, D. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.713438 · Cited by 478 · cited 2×
“Indeed a recent post hoc analysis was performed using combined data of the ‘Treating to New Targets’-TNT trial and the ‘Incremental Decrease in End Points through Aggressive Lipid Lowering’-IDEAL trial and it revealed that on-treatment levels of non-HDL-C but also apoB were more closely associated with cardiovascular…”
BackgroundMethodMora, S., Rifai, N., Buring, J. E., & Ridker, P. M. (2008) · Circulation · doi:10.1161/circulationaha.108.777334 · Cited by 445
Non-HDL Cholesterol as a Predictor of Cardiovascular Disease in Type 2 Diabetes
Lu, W., Resnick, H. E., Jablonski, K. A., Jones, K. L., Jain, A. K., Howard, W. J., Robbins, D. C., & Howard, B. V. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.16 · Cited by 370
Austin, M. A., McKnight, B., Edwards, K. L., Bradley, C. M., McNeely, M. J., Psaty, B. M., Brunzell, J. D., & Motulsky, A. G. (2000) · Circulation · doi:10.1161/01.cir.101.24.2777 · Cited by 255
Mahley, R. W., & Huang, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30889 · Cited by 159 · cited 1×
“The remaining apoB-48 containing chylomicron remnants will be directly taken up by the liver through a concerted action of heparin sulphate proteoglycans (HSPG), which can rapidly bind apoB-48, LDL receptor-related protein 1 (LRP1) and by the LDL-receptor located on the plasma membrane that will bind apoE present on t…”
BackgroundStalenhoef, A. F., & de Graaf, J. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328304b63c · Cited by 121 · cited 1×
“Presence of elevated concentrations of atherogenic TGrich remnant lipoproteins is the principle abnormality responsible for this association [23].”
BackgroundGinsberg, H. N., Bonds, D. E., Lovato, L. C., Crouse, J. R., Elam, M. B., Linz, P. E., O’Connor, P. J., Leiter, L. A., Weiss, D., Lipkin, E., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.024 · Cited by 95
Blasiole, D. A., Oler, A. T., & Attie, A. D. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710457200 · Cited by 65 · cited 1×
“It has since long been recognized that fatty acids are important ligands for several nuclear receptors that control lipid metabolism [21].”
Background
Cited by
Geller, B. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1508 · Cited by 281
Hong, F., Xu, P., & Zhai, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082189 · Cited by 139
“3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoA) inhibitors or statins have demonstrated a significant reduction in CVD risk in a large number of landmark trials [156].”
BackgroundInfluentialHalcox, J. P., Banegas, J. R., Roy, C., Dallongeville, J., De Backer, G., Guallar, E., Perk, J., Hajage, D., Henriksson, K. M., & Borghi, C. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0591-5 · Cited by 122
“Whether or not TG levels are a causal risk factor for CVD is debated [22, 23]; patients with high TG levels often have additional CVD risk factors; TG levels in human plasma are highly variable and are strongly associated with low HDL-C levels, which makes it difficult to separate the contributions of these two compon…”
BackgroundKumari, S., Deori, M., Elancheran, R., Kotoky, J., & Devi, R. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00400 · Cited by 105
“…triglyceride (TG) and remains one of the major risk factors for coronary heart diseases (CHD), especially, the increased plasma low-density lipoprotein level can accelerate atherosclerosis (Arsenault et al., 2009; Harchaoui et al., 2009; de Lemos et al., 2010; Berry et al., 2012; Ma et al., 2012).”
BackgroundPiltonen, T., Puurunen, J., Hedberg, P., Ruokonen, A., Mutt, S. J., Herzig, K. H., Nissinen, A., Morin-Papunen, L., & Tapanainen, J. S. (2012) · Human Reproduction · doi:10.1093/humrep/des225 · Cited by 94
Metadata
- Authors
- Harchaoui, K., Visser, M., Kastelein, J., Stroes, E., & Dallinga-Thie, G.
- Venue
- Current Cardiology Reviews
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-08-01
- Volume
- 5
- Issue
- 3
- Pages
- 216-222
- ISSN
- 1573-403X (ISSN-L)
- OpenAlex
- W2122908785
- Cited by
- 136
- References
- 19
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.